{"entity":{"id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","aka":[],"tldr":"A phase 2 trial of sacituzumab tirumotecan and toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is a phase 2, interventional study registered as NCT07244874 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 41 participants, started 2025-12-01 and due to reach its primary completion in 2028-01-30. Interventions recorded: Sacituzumab tirumotecan; Toripalimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; PD-L1 Positive. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07244874","url":"https://clinicaltrials.gov/study/NCT07244874"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["sacituzumab-tirumotecan","toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07244874","phase":"2","setting":"A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":41,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07244874/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}